Blog
RSS FeedPosted by Michael Wonder on 16 May 2022
Japan pharma lobbies say pricing scheme leading to renewed 'drug lag'
16 May 2022 - Japan's three major pharmaceutical lobbies joined for the first time on Monday in urging reforms to ...
Posted by Michael Wonder on 13 May 2022
The man behind ‘value based pricing’ saw pharma distorting his message — and walked away
13 May 2022 - When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company gave ...
Posted by Michael Wonder on 25 Apr 2022
Is it best to remove insurance benefits from drugs prescribed in bribery?
25 April 2022 - The Ministry of Health and Welfare’s Health Insurance Policy Review Committee is scheduled to hold a ...
Posted by Michael Wonder on 19 Apr 2022
Supply related data in manufacturer dossiers: things are not going smoothly yet
19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science. ...
Posted by Michael Wonder on 18 Mar 2022
Update to the statutory scheme to control the costs of branded health service medicines
15 March 2022 - The UK Government is seeking views on its proposal to increase the rate of payments made ...
Posted by Michael Wonder on 15 Mar 2022
Drug industry says EMA’s PRIME scheme useful but could be improved
14 March 2022 - Eligibility criteria for admission to the EMA's priority medicines (PRIME) scheme are too strict to facilitate ...
Posted by Michael Wonder on 03 Mar 2022
PhRMA Statement on the State of the Union Address
1 March 2022 - The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the ...
Posted by Michael Wonder on 25 Feb 2022
MAP offers new online pathway for accessing cancer treatments
25 February 2022 - Medicines Australia and Rare Cancers Australia yesterday provided pharmaceutical industry stakeholders a preview of a new ...
Posted by Michael Wonder on 22 Feb 2022
Does the DoH favour some pharmaceutical companies over others?
23 February 2022 - Some interesting insights from version 1 of the agenda for the May 2022 PBAC (intracycle) meeting. ...
Posted by Michael Wonder on 21 Feb 2022
COVID-19 pandemic sends clear message that Australia must value the long-term health of all Australians
21 February 2022 - Medicines Australia is warning that Australia must act now to ensure that our health system is ...
Posted by Michael Wonder on 31 Jan 2022
Drug makers raised prices by 6.6% on average early this year
30 January 2022 - The companies kept most increases in the single digits for another year as Congress explores measures to ...
Posted by Michael Wonder on 31 Jan 2022
Fables and misperceptions about drug makers and drug pricing are misleading customers about the value the industry provides
27 January 2022 - In my last column, I discussed the need for the pharmaceutical industry to more publicly highlight the ...
Posted by Michael Wonder on 30 Jan 2022
Medicines regulator pilot probes pharma delays in market launches
25 January 2022 - The European Medicines Agency wants to get a better understanding of drug companies’ commercial intentions and why. ...
Posted by Michael Wonder on 28 Jan 2022
Australians deserve fast access to the latest medicines, vaccines and treatments
28 January 2022 - Medicines Australia recommends the Australian Government delivers a plan to shorten the time that patients wait ...
Posted by Michael Wonder on 14 Dec 2021
mRNA manufacturing facility will deliver long term health benefits for Australians
14 December 2021 - Medicines Australia welcomes the announcement that Australia will manufacture mRNA vaccines in a deal struck with ...